Collegium Pharmaceutical, Inc. $COLL Stock: Smith Group Asset Management LLC Reduces Stake

Key Points

• Smith Group Asset Management cut its Collegium Pharmaceutical stake by 69.5% in the third quarter, selling 51,352 shares and retaining 22,544 shares valued at about $492,000.
• Other institutional investors were more supportive, with BlackRock and Jupiter Topco initiating sizable positions while Janus Henderson and Arrowstreet Capital increased their holdings.
• Collegium reported quarterly EPS of $1.92, beating estimates by $0.20, while revenue rose 6.3% year over year to $199.88 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $48.71, well above the reported $23.23 share price.

Smith Group Asset Management LLC reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 69.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,544 shares of the specialty pharmaceutical company's stock after selling 51,352 shares during the period. Smith Group Asset Management LLC owned 0.07% of Collegium Pharmaceutical worth $492,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $196,972,000. Jupiter Topco LLC bought a new position in Collegium Pharmaceutical in the second quarter worth approximately $77,743,000. Janus Henderson Group PLC grew its stake in Collegium Pharmaceutical by 26.0% in the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock worth $60,358,000 after purchasing an additional 377,073 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Collegium Pharmaceutical by 0.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company's stock worth $27,551,000 after purchasing an additional 2,712 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Collegium Pharmaceutical by 29.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 703,528 shares of the specialty pharmaceutical company's stock worth $23,266,000 after purchasing an additional 159,755 shares during the period.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $23.23 on Thursday. The company has a 50 day moving average price of $23.47 and a 200-day moving average price of $33.59. Collegium Pharmaceutical, Inc. has a fifty-two week low of $21.43 and a fifty-two week high of $50.79. The stock has a market capitalization of $756.37 million, a PE ratio of 18.73, a PEG ratio of 0.71 and a beta of 0.73. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company's quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the firm earned $1.68 earnings per share. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on COLL. Zacks Research raised Collegium Pharmaceutical from a "strong sell" rating to a "strong-buy" rating in a research report on Thursday, October 15th. Piper Sandler reissued a "neutral" rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Oppenheimer initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $50.00 price target on the stock. Leerink Partners began coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an "outperform" rating and a $45.00 price target on the stock. Finally, Wall Street Zen downgraded Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $48.71.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.